View Older Stories
-
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
-
Evotec SE (EVO) Receives Grants to Advance Tuberculosis Treatment
-
Evotec Receives Grants to Advance Tuberculosis Treatment
-
Evotec nominates Dr. Wolfgang Hofmann to supervisory board
-
Evotec Announces New Nomination to Board of Directors
-
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
-
Evotec names Claire Hinshelwood as new CFO, replacing Paul Hitchin
-
Evotec Announces Chief Financial Officer Transition
-
H.C. Wainwright Assumes Evotec (EVO) at Buy
-
Evotec appoints Dr. Ingrid Müller as chief operating officer
-
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
-
BofA Securities on Evotec (EVO): guidance 'embeds a high degree of reliance on 2H recovery'
-
Evotec nominates Dieter Weinand as supervisory board chairman
-
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
-
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
-
Evotec names Dr. Ashiq Khan as chief commercial officer
-
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
-
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
-
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
-
Berenberg Starts Evotec AG (EVT:GR) (EVO) at Buy
-
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
-
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
-
Evotec SE (EVO) Reports Q3 results; offers guidance
-
Evotec receives $25 million from Bristol Myers Squibb for neuroscience work
-
Evotec (EVO) PT Lowered to $7 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Evotec (EVO)
-
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
-
Evotec SE (EVO) Comment on Withdrawn Non-Binding Offer from Halozyme (HALO)
-
Comment on Withdrawn Non-Binding Offer
-
Halozyme Therapeutics (HALO) Withdraws Proposal to Acquire Evotec (EVO) Following Evotec's Unwillingness to Engage in Discussions
-
Halozyme Therapeutics (HALO) Provides Update on Non-Binding Proposal to Combine with Evotec (EVO)
-
Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)
-
Comment on Media Report
-
After-hours movers: Applied Materials, Domino's Pizza, Evotec
-
Halozyme Therapeutics (HALO) Confirms Proposal to Combine with Evotec (EVO) for €11.00 Per Share in an All-Cash Transaction
-
Evotec (EVO) Is Said To Attract Takeover Interest From Halozyme (HALO) - Bloomberg
-
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
-
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
-
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
-
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
-
Jefferies Downgrades Evotec (EVO) to Hold
-
Jefferies Downgrades Evotec AG (EVT:GR) (EVO) to Hold
-
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
-
Evotec Announces Change in Management Board
-
With stock down 73% YTD, is Evotec a broken business?
-
Evotec AG (EVT:GR) (EVO) PT Lowered to EUR12 at RBC Capital
-
Evotec (EVO) PT Lowered to $8 at H.C. Wainwright
-
Evotec (EVO) PT Lowered to $3 at BofA Securities
-
Deutsche Bank Downgrades Evotec AG (EVT:GR) (EVO) to Sell
-
Midday movers: Super Micro Computer, Airbnb and Lyft fall; Shopify rises

